Denali Therapeutics Inc DNLI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DNLI is a good fit for your portfolio.
News
-
Thinking about buying stock in QuickLogic, Ventyx Biosciences, Denali Therapeutics, Beyond Meat, or Archer Aviation?
-
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
-
Denali Therapeutics Announces $500 million Private Placement Equity Financing
-
Denali Therapeutics Shares Fall After ALS Treatment Misses Primary Endpoint
-
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
-
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
Trading Information
- Previous Close Price
- $16.58
- Day Range
- $15.92–16.80
- 52-Week Range
- $15.45–33.10
- Bid/Ask
- $16.09 / $16.11
- Market Cap
- $2.23 Bil
- Volume/Avg
- 690,690 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.90
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 445
Comparables
Valuation
|
Metric
|
DNLI
|
CBAY
|
VRDN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.23 | 12.65 | 3.48 |
Price/Sales | 6.90 | 111.01 | 2,160.78 |
Price/Cash Flow | — | — | — |
Price/Earnings
DNLI
CBAY
VRDN
Financial Strength
|
Metric
|
DNLI
|
CBAY
|
VRDN
|
|---|---|---|---|
Quick Ratio | 13.31 | 10.70 | 17.93 |
Current Ratio | 13.65 | 10.96 | 18.26 |
Interest Coverage | — | −5.27 | −137.76 |
Quick Ratio
DNLI
CBAY
VRDN
Profitability
|
Metric
|
DNLI
|
CBAY
|
VRDN
|
|---|---|---|---|
Return on Assets (Normalized) | −4.56% | −30.06% | −42.76% |
Return on Equity (Normalized) | −5.60% | −51.97% | −82.42% |
Return on Invested Capital (Normalized) | −8.94% | −30.87% | −50.70% |
Return on Assets
DNLI
CBAY
VRDN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dvzvclwmr | Wnyv | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pwkgtwkwc | Pwtwn | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nvflpmgy | Mbfwcz | $98.1 Bil | |
MRNA
| Moderna Inc | Xlfkgxq | Lfrv | $39.1 Bil | |
ARGX
| argenx SE ADR | Lbncwym | Lcfqx | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Pqjkxztsy | Rgcy | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hlhcqkyvh | Fhsvmlp | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nqbpzdph | Htqzhh | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wpwkcqyh | Qpvfsy | $12.5 Bil | |
INCY
| Incyte Corp | Nbxlhpv | Fxzykx | $11.9 Bil |